Aurinia Pharmaceuticals Inc. (AUPH) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Aurinia Pharmaceuticals Inc. (AUPH) closed at USD 16.61 on 2026-10-14, a change of +31.5 % over the past year, with a market capitalization of USD 2.23B.

Aurinia Pharmaceuticals Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Aurinia Pharmaceuticals Inc. key figures

Previous close

USD 16.61 (2026-10-14)

1-year change

+31.5 %

Market cap

USD 2.23B

Enterprise value

USD 1.85B

P/E ratio (trailing)

7.18

P/E ratio (forward)

15.68

EPS (trailing)

2.33

EPS (forward)

1.07

PEG ratio

n/a

Price to book

3.62

Revenue growth

18.9 %

Earnings growth

75.5 %

Dividend per share (trailing)

0.00

Short ratio

9.71

Employees

128

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Aurinia Pharmaceuticals Inc. and compare it with other stocks.